| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Buthionine suLfoximine is a methionine suLfoximine analogue that exhibits at least 100 times the efficiency of methionine suLfoximine in inhibiting γ-glutamylcysteine synthetase, compared to around 20 times that of methionine suLfoximine [1].
|
|---|---|
| ln Vivo |
A continuous intravenous infusion of non-toxic dosages of D,L-buthionine-(S,R)-imine (300 and 600 mg/kg/day) was administered to mice containing HT1080 and HT1080/DR4 xenografts. GSH tumor levels are decreased by more than 95% in multidrug additions and commonly decrease by 60% in parent cancers [2].
|
| References |
|
| Additional Infomation |
S-butyl-DL-homocysteine (S,R)-sulfoximine is a sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl. It has a role as an EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor and a ferroptosis inducer. It contains a D-buthionine-(S,R)-sulfoximine and a L-buthionine-(S,R)-sulfoximine.
Buthionine sulfoximine has been used in trials studying the treatment of Neuroblastoma and Melanoma (Skin). Buthionine Sulfoximine is a synthetic amino acid. Buthionine sulfoximine irreversibly inhibits gamma-glutamylcysteine synthase, thereby depleting cells of glutathione, a metabolite that plays a critical role in protecting cells against oxidative stress, and resulting in free radical-induced apoptosis. Elevated glutathione levels are associated with tumor cell resistance to alkylating agents and platinum compounds. By depleting cells of glutathione, this agent may enhance the in vitro and in vivo cytotoxicities of various chemotherapeutic agents in drug-resistant tumors. Buthionine sulfoximine may also exhibit antiangiogenesis activity. (NCI04) A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7) |
| Molecular Formula |
C8H18N2O3S
|
|---|---|
| Molecular Weight |
222.303
|
| Exact Mass |
222.104
|
| CAS # |
5072-26-4
|
| Related CAS # |
L-Buthionine-(S,R)-sulfoximine;83730-53-4;DL-Buthionine-(S,R)-sulfoximine hydrochloride;L-Buthionine-(S,R)-sulfoximine hydrochloride
|
| PubChem CID |
21157
|
| Appearance |
White to off-white solid powder
|
| Density |
1.29g/cm3
|
| Boiling Point |
382.3ºC at 760 mmHg
|
| Melting Point |
215ºC (dec.)(lit.)
|
| Flash Point |
185ºC
|
| Index of Refraction |
1.537
|
| LogP |
2.301
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
14
|
| Complexity |
284
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KJQFBVYMGADDTQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)
|
| Chemical Name |
2-amino-4-(butylsulfonimidoyl)butanoic acid
|
| Synonyms |
Buthionine Sulphoximine; BSO; NSC-326231
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~25 mg/mL (~112.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (449.82 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4984 mL | 22.4921 mL | 44.9843 mL | |
| 5 mM | 0.8997 mL | 4.4984 mL | 8.9969 mL | |
| 10 mM | 0.4498 mL | 2.2492 mL | 4.4984 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
